Piotr Adamowicz / Shutterstock.com
AstraZeneca has filed a citizen petition to the US Food and Drug Administration (FDA) requesting it to wait until 2023 before approving generic versions of Crestor (rosuvastatin calcium), a cholesterol treatment.
Start a subscription today to access the LSIPR website.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’.
AstraZeneca, citizen petition, FDA, Crestor, generics, US Food and Drug Administration, orphan drug
